# Phase 2a Study of VTX3232 in Parkinson's Disease

> **NCT06556173** · PHASE2 · COMPLETED · sponsor: **Zomagen Biosciences Ltd.** · enrollment: 11 (actual)

## Conditions studied

- Idiopathic Parkinson Disease

## Interventions

- **DRUG:** VTX3232

## Key facts

- **NCT ID:** NCT06556173
- **Lead sponsor:** Zomagen Biosciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-08
- **Primary completion:** 2025-04-04
- **Final completion:** 2025-04-04
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06556173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06556173, "Phase 2a Study of VTX3232 in Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06556173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*